Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06677333 · ClinicalTrials.gov registry record · NA
The Effect of Increasing Dietary Protein on the Gut Microbiome and Its Metabolites
A NA study of Health Adults, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT06677333: Completed NA study of Health Adults, sponsored by Louisiana State University Health Sciences Center in New Orleans.
NCT06677333 is a NA study of Health Adults that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06677333, a NA study of Health Adults, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effect of dietary protein not absorbed in the small intestine on the bacteria in the large intestine and the metabolites those bacteria produce when they break down the protein. The three specific goals are: 1. Determine if increasing dietary protein increases the purine breakdown product, allantoin, as observed in our previous study. 2. Establish a model to examine the effect of dietary protein on the gut microbiota and metabolites. 3. Identify gut bacteria and metabolite changes that occur with increased consumption of animal (whey) or plant (pea) protein sources.
Primary Outcome
A cross-sectional study the investigators conducted found that healthy individuals who reported consuming, on average, 150 gms of protein daily had a higher fecal allantoin. This study is a pre/post-randomized controlled trial to confirm that observation. It will determine if consuming 50 gms more protein daily increases fecal allantoin.
Conditions Studied
Interventions
- OTHER Whey Protein
- OTHER Pea protein
Study Locations (1)
Louisiana
- Louisiana State University Health Sciences Center New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2023-11-30 |
| Phase | NA |
What the finished NCT06677333 record still lists
NCT06677333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Health Adults appearing as the primary indexed condition, and to 2 interventions - of which Whey Protein is the first listed.
NCT06677333 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06677333 about?
NCT06677333 is a clinical study titled "The Effect of Increasing Dietary Protein on the Gut Microbiome and Its Metabolites". This study will determine the effect of dietary protein not absorbed in the small intestine on the bacteria in the large intestine and the metabolites those bacteria produce when they break down the protein. The three specific goals are: 1. Determine if increasing dietary protein increases the puri...
What is the current status of trial NCT06677333?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2023-02-01. Estimated completion is 2023-11-30.
What conditions does trial NCT06677333 study?
This clinical trial studies the following conditions: Health Adults.
What interventions are being tested in trial NCT06677333?
The interventions under investigation include: Whey Protein (OTHER), Pea protein (OTHER).
Who is sponsoring clinical trial NCT06677333?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06677333 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06677333's enrollment target sits among peer trials
87 974th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI